drugset / Trial / NCT02172157
Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary objective: To determine the basic pharmacokinetics of BI 1744 BS, its metabolite BI 1744 BS - glucuronide and \[14C\]-radioactivity including excretion mass balance, excretion pathways and metabolism following intravenous and oral administration of \[14C\]BI 1744 CL Secondary objective: To determine safety and tolerability following intravenous and oral administration of \[14C\]BI 1744 CL in healthy male subjects
Timeline
- Start
- 2008-02
- Primary completion
- 2008-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olodaterol | Small molecule | 20 ug | Intravenous |
| Subject | Olodaterol | Small molecule | 40 ug | Intravenous |
Indications
No indication recorded.